Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.
Burosumab
Patient-reported outcomes
Patient-reported outcomes measurement information system
X-linked hypophosphatemia
Journal
Calcified tissue international
ISSN: 1432-0827
Titre abrégé: Calcif Tissue Int
Pays: United States
ID NLM: 7905481
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
01
10
2020
accepted:
14
12
2020
pubmed:
24
1
2021
medline:
19
8
2021
entrez:
23
1
2021
Statut:
ppublish
Résumé
Changing to burosumab, a monoclonal antibody targeting fibroblast growth factor 23, significantly improved phosphorus homeostasis, rickets, lower-extremity deformities, mobility, and growth versus continuing oral phosphate and active vitamin D (conventional therapy) in a randomized, open-label, phase 3 trial involving children aged 1-12 years with X-linked hypophosphatemia. Patients were randomized (1:1) to subcutaneous burosumab or to continue conventional therapy. We present patient-reported outcomes (PROs) from this trial for children aged ≥ 5 years at screening (n = 35), using a Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire and SF-10 Health Survey for Children. PROMIS pain interference, physical function mobility, and fatigue scores improved from baseline with burosumab at weeks 40 and 64, but changed little with continued conventional therapy. Pain interference scores differed significantly between groups at week 40 (- 5.02, 95% CI - 9.29 to - 0.75; p = 0.0212) but not at week 64. Between-group differences were not significant at either week for physical function mobility or fatigue. Reductions in PROMIS pain interference and fatigue scores from baseline were clinically meaningful with burosumab at weeks 40 and 64 but not with conventional therapy. SF-10 physical health scores (PHS-10) improved significantly with burosumab at week 40 (least-squares mean [standard error] + 5.98 [1.79]; p = 0.0008) and week 64 (+ 5.93 [1.88]; p = 0.0016) but not with conventional therapy (between-treatment differences were nonsignificant). In conclusion, changing to burosumab improved PRO measures, with statistically significant differences in PROMIS pain interference at week 40 versus continuing with conventional therapy and in PHS-10 at weeks 40 and 64 versus baseline.Trial registration: ClinicalTrials.gov NCT02915705.
Identifiants
pubmed: 33484279
doi: 10.1007/s00223-020-00797-x
pii: 10.1007/s00223-020-00797-x
pmc: PMC8064984
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
burosumab
G9WJT6RD29
Banques de données
ClinicalTrials.gov
['NCT02915705']
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
622-633Références
Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL (2011) A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381–1388. https://doi.org/10.1002/jbmr.340
doi: 10.1002/jbmr.340
pubmed: 21538511
pmcid: 3157040
Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, Imel EA (2019) Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol 3:189–199. https://doi.org/10.1016/S2213-8587(18)30338-3
doi: 10.1016/S2213-8587(18)30338-3
Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, Kamenicky P, Nevoux J, Prié D, Rothenbuhler A, Wicart P, Harvengt P (2014) Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 3:R13–R30. https://doi.org/10.1530/EC-13-0103
doi: 10.1530/EC-13-0103
pubmed: 24550322
pmcid: 3959730
Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, Theodore-Oklota C, San Martin J (2019) The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc 3:1321–1334. https://doi.org/10.1210/js.2018-00365
doi: 10.1210/js.2018-00365
pubmed: 31259293
pmcid: 6595532
Collins M (2018) Burosumab: at long last, an effective treatment for FGF23-associated hypophosphatemia. J Bone Miner Res 33:1381–1382. https://doi.org/10.1002/jbmr.3544
doi: 10.1002/jbmr.3544
pubmed: 29989668
Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, Kawakami T, Ito T, Zhang Z, Humphrey J, Insogna KL, Peacock M (2014) Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 124:1587–1597. https://doi.org/10.1172/JCI72829
doi: 10.1172/JCI72829
pubmed: 24569459
pmcid: 3973088
Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO (2015) Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab 100:2565–2573. https://doi.org/10.1210/jc.2015-1551
doi: 10.1210/jc.2015-1551
pubmed: 25919461
pmcid: 4495171
Carpenter TO, Whyte MP, Imel EA, Boot AM, Högler W, Linglart A, Padidela R, Van’t Hoff W, Mao M, Chen C-Y, Skrinar A, Kakkis E, San Martin J, Portale AA (2018) Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378:1987–1998. https://doi.org/10.1056/NEJMoa1714641
doi: 10.1056/NEJMoa1714641
pubmed: 29791829
Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen C-Y, Skrinar A, San Martin J, Portale AA (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393:2416–2427. https://doi.org/10.1016/S0140-6736(19)30654-3
doi: 10.1016/S0140-6736(19)30654-3
pubmed: 31104833
pmcid: 7179969
Broderick JE, DeWitt EM, Rothrock N, Crane PK, Forrest CB (2013) Advances in patient-reported outcomes: the NIH PROMIS® measures. EGEMS (Wash DC) 1:1015. https://doi.org/10.13063/2327-9214.1015
doi: 10.13063/2327-9214.1015
HealthMeasures (2020) Measure Development & Research. Northwestern University. http://www.healthmeasures.net/explore-measurement-systems/promis/measure-development-research . Accessed 15 Sept 2020.
Nixon A, Williams A, Skrinar A, Theodore-Oklota C (2019) Psychometric validation of the PROMIS
HealthMeasures (2020) PROMIS. Northwestern University. http://www.healthmeasures.net/explore-measurement-systems/promis . Accessed 15 Sept 2020.
Irwin DE, Stucky BD, Thissen D, DeWitt EM, Lai JS, Yeatts K, Varni JW, DeWalt DA (2010) Sampling plan and patient characteristics of the PROMIS pediatrics large-scale survey. Qual Life Res 19:585–594. https://doi.org/10.1007/s11136-010-9618-4
doi: 10.1007/s11136-010-9618-4
pubmed: 20204706
pmcid: 3157238
Saris-Baglama RN, DeRosa MA, Raczek AE, Bjorner JB, Turner-Bowker DM, Ware JE (2007) The SF-10
Hicks CL, von Baeyer CL, Spafford PA, van Korlaar I, Goodenough B (2001) The faces pain scale-revised: toward a common metric in pediatric pain measurement. Pain 93:173–183. https://doi.org/10.1016/s0304-3959(01)00314-1
doi: 10.1016/s0304-3959(01)00314-1
pubmed: 11427329
Thacher TD, Pettifor JM, Tebben PJ, Creo AL, Skrinar A, Mao M, Chen C-Y, Chang T, San Martin J, Carpenter TO (2019) Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: utility of the radiographic rickets severity score. Bone 122:76–81. https://doi.org/10.1016/j.bone.2019.02.010
doi: 10.1016/j.bone.2019.02.010
pubmed: 30772600
Thissen D, Liu Y, Magnus B, Quinn H, Gipson DS, Dampier C, Huang I-C, Hinds PS, Selewski DT, Reeve BB, Gross HE, DeWalt DA (2016) Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method. Qual Life Res 25:13–23. https://doi.org/10.1007/s11136-015-1058-8
doi: 10.1007/s11136-015-1058-8
pubmed: 26118768
Wyrwich KW, Norquist JM, Lenderking WR, Acaster S (2013) Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res 22:475–483. https://doi.org/10.1007/s11136-012-0175-x
doi: 10.1007/s11136-012-0175-x
pubmed: 22528240
DeWalt DA, Gross HE, Gipson DS, Selewski DT, DeWitt EM, Dampier CD, Hinds PS, Huang I-C, Thissen D, Varni JW (2015) PROMIS
doi: 10.1007/s11136-015-0953-3
pubmed: 25715946
pmcid: 4531096
Arvanitis M, DeWalt DA, Martin CF, Long MD, Chen W, Jaeger B, Sandler RS, Kappelman MD (2016) Patient-reported outcomes measurement information system in children with Crohn’s disease. J Pediatr 174:153-159.e2. https://doi.org/10.1016/j.jpeds.2016.03.069
doi: 10.1016/j.jpeds.2016.03.069
pubmed: 27157449
pmcid: 5157125
Brandon TG, Becker BD, Bevans KB, Weiss PF (2017) Patient-reported outcomes measurement information system tools for collecting patient-reported outcomes in children with juvenile arthritis. Arthritis Care Res (Hoboken) 69:393–402. https://doi.org/10.1002/acr.22937
doi: 10.1002/acr.22937
Cunningham NR, Kashikar-Zuck S, Mara C, Goldschneider KR, Revicki DA, Dampier C, Sherry DD, Crosby L, Carle A, Cook KF, Morgan EM (2017) Development and validation of the self-reported PROMIS pediatric pain behavior item bank and short form scale. Pain 158:1323–1331. https://doi.org/10.1097/j.pain.0000000000000914
doi: 10.1097/j.pain.0000000000000914
pubmed: 28394851
pmcid: 5996986
Dampier C, Barry V, Gross HE, Lui Y, Thornburg CD, DeWalt DA, Reeve BB (2016) Initial evaluation of the pediatric PROMIS
doi: 10.1002/pbc.25944
pubmed: 26895143
pmcid: 4833539
Dampier C, Jaeger B, Gross HE, Barry V, Edwards L, Lui Y, DeWalt DA, Reeve BB (2016) Responsiveness of PROMIS
doi: 10.1002/pbc.25931
pubmed: 26853841
pmcid: 5055833
Reeve BB, Edwards LJ, Jaeger BC, Hinds PS, Dampier C, Gipson DS, Selewski DT, Troost JP, Thissen D, Barry V, Gross HE, DeWalt DA (2018) Assessing responsiveness over time of the PROMIS
doi: 10.1007/s11136-017-1697-z
pubmed: 28884421
Jones JT, Carle AC, Wootton J, Liberio B, Lee J, Schanberg LE, Ying J, DeWitt EM, Brunner HI (2017) Validation of patient-reported outcomes measurement information system short forms for use in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 69:133–142. https://doi.org/10.1002/acr.22927
doi: 10.1002/acr.22927
Theunissen NC, Vogels TG, Koopman HM, Verrips GH, Zwinderman KA, Verloove-Vanhorick SP, Wit JM (1998) The proxy problem: child report versus parent report in health-related quality of life research. Qual Life Res 7:387–397. https://doi.org/10.1023/A:1008801802877
doi: 10.1023/A:1008801802877
pubmed: 9691719
Lyseng-Williamson KA (2018) Burosumab in X-linked hypophosphatemia: a profile of its use in the USA. Drugs Ther Perspect 34:497–506. https://doi.org/10.1007/s40267-018-0560-9
doi: 10.1007/s40267-018-0560-9
pubmed: 30459508
pmcid: 6223702
Veilleux LN, Cheung M, Ben Amor M, Rauch F (2012) Abnormalities in muscle density and muscle function in hypophosphatemic rickets. J Clin Endocrinol Metab 97:E1492–E1498. https://doi.org/10.1210/jc.2012-1336
doi: 10.1210/jc.2012-1336
pubmed: 22639288
Pesta DH, Tsirigotis DN, Befroy DE, Caballero D, Jurczak MJ, Rahimi Y, Cline GW, Dufour S, Birkenfeld AL, Rothman DL, Carpenter TO, Insogna K, Petersen KF, Bergwitz C, Shulman GI (2016) Hypophosphatemia promotes lower rates of muscle ATP synthesis. FASEB J 30:3378–3387. https://doi.org/10.1096/fj.201600473R
doi: 10.1096/fj.201600473R
pubmed: 27338702
pmcid: 5024687
Chen YY, Kao TW, Chou CW, Wu CJ, Yang HF, Lai CH, Wu LW, Chen WL (2018) Exploring the link between serum phosphate levels and low muscle strength, dynapenia, and sarcopenia. Sci Rep 8:3573. https://doi.org/10.1038/s41598-018-21784-1
doi: 10.1038/s41598-018-21784-1
pubmed: 29476104
pmcid: 5824959
Allen DG, Trajanovska S (2012) The multiple roles of phosphate in muscle fatigue. Front Physiol 3:463. https://doi.org/10.3389/fphys.2012.00463
doi: 10.3389/fphys.2012.00463
pubmed: 23248600
pmcid: 3518787
van Onzenoort HA, Menger FE, Neef C, Verbeck WJ, Kroon AA, de Leeuw PW, van der Kuyet PHM (2011) Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension 58:573–578. https://doi.org/10.1161/HYPERTENSIONAHA.111.171074
doi: 10.1161/HYPERTENSIONAHA.111.171074
pubmed: 21825228
Carls GS, Tuttle E, Tan RD, Huyuh J, Yee J, Edelman SV, Polonsky WH (2017) Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes. Diabetes Care 40:1469–1478. https://doi.org/10.2337/dc16-2725
doi: 10.2337/dc16-2725
pubmed: 28801475
Mauro MJ, Davis C, Zyczynski T, Khoury HJ (2015) The role of observational studies in optimizing the clinical management of chronic myeloid leukemia. Ther Adv Hematol 6:3–14. https://doi.org/10.1177/2040620714560305
doi: 10.1177/2040620714560305
pubmed: 25642311
pmcid: 4298489
Tobert JA, Newman CB (2016) Statin tolerability: in defence of placebo-controlled trials. Eur J Prev Cardiol 23:891–896. https://doi.org/10.1177/2047487315602861
doi: 10.1177/2047487315602861
pubmed: 26318980